Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000935538p
Ethics application status
Submitted, not yet approved
Date submitted
22/07/2024
Date registered
1/08/2024
Date last updated
1/08/2024
Date data sharing statement initially provided
1/08/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
68Ga-NTA-476 Imaging in Men with Prostate Cancer
Query!
Scientific title
A Single-Arm Comparative Imaging study to evaluate the uptake of 68Ga-NTA-476 on PET/CT Compared to Standard of Care 18F-DCFPyL PET/CT in Men with Prostate Cancer
Query!
Secondary ID [1]
312504
0
None
Query!
Universal Trial Number (UTN)
U1111-1310-4819
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer
334362
0
Query!
Condition category
Condition code
Cancer
331009
331009
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The novel Prostate Specific Membrane Antigen (PSMA) targeting molecule, NTA-476, is comprised of a small peptide targeting moiety that is attached to a linker and dodecane tetraacetic acid (DOTA) cage which enables chelation of the radionuclide 68Ga for Positron Emission Tomography (PET) imaging.
A single dose of 68Ga-NTA-476 will be administered on Day 1 of the study as an intravenous bolus injection under the supervision of the study Investigator or appropriately qualified delegate. The planned injected activity (IA) of 68Ga-NTA-476 is 2-3.5 MBq/kg.
Following administration of 68Ga-NTA-476, participants will complete PET imaging at 0-30 minutes, 1 hour, and 4-6 hours. Each PET scan will take up to 30 minutes.
As there is only a single intravenous injection of 68Ga-NTA-476 administered in this study, there are no strategies required to monitor adherence.
Query!
Intervention code [1]
329022
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
68Ga-NTA-476 will be compared to 18F-DCFPyL imaging. Standard of care 18F-DCFPyL imaging will be obtained prior to participation in the trial as part of standard clinical care or during the screening period if not completed within the past 6 weeks.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
338771
0
Tumour uptake of 68Ga-NTA-476 as compared to 15F-DCFPyl in participants with prostate cancer
Query!
Assessment method [1]
338771
0
Standardised Uptake Value (SUV)max, SUVmean and total tumour volume by PET/CT quantitation
Query!
Timepoint [1]
338771
0
PET/CT scans completed at 0-30 minutes, 1 hour, and 4-6 hours following 68Ga-NTA-476 administration
Query!
Primary outcome [2]
338772
0
To characterize the uptake and washout of 68Ga-NTA-476 in normal organs as compared to 18F-DCFPyL in participants with prostate cancer. These will be assessed as a composite outcome.
Query!
Assessment method [2]
338772
0
Time Activity Curves (TACs), describing % of the injected activity vs time will be derived for selected organs and tumours
Query!
Timepoint [2]
338772
0
PET/CT scans completed at 0-30 minutes, 1 hour, and 4-6 hours following 68Ga-NTA-476 administration
Query!
Secondary outcome [1]
437392
0
To assess the safety and tolerability of a single dose of 68Ga-NTA-476
Query!
Assessment method [1]
437392
0
Safety is evaluated with the properties, incidence, nature and severity of AEs and SAEs, abnormal laboratory parameters, vital signs, and electrocardiogram (ECG) results per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. This is a first in human trial so possible reactions are yet unknown.
Query!
Timepoint [1]
437392
0
Safety will be assessed on the Imaging Day in the clinic during observation for up to 6 hours post injection of 68Ga-NTA-476 and followed up for a total of 1 week following administration.
Query!
Secondary outcome [2]
437393
0
To explore the dosimetry of 68Ga-NTA-476
Query!
Assessment method [2]
437393
0
Absorbed radiation doses of 68Ga-NTA-476 in critical organs (e.g., kidneys, bone marrow)
Query!
Timepoint [2]
437393
0
PET/CT scans completed at 0-30 minutes, 1 hour, and 4-6 hours following 68Ga-NTA-476 administration
Query!
Eligibility
Key inclusion criteria
1. Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.
2. Adult participants greater than or equal to 18 years of age.
3. Participants with a documented history of histologically confirmed diagnosis of prostate cancer.
o Participants must have PSA > 0.1 ng/mL.
o Participants on chemotherapy may be approved on a case-by-case basis at the principal investigator's discretion if the last dose of chemotherapy is administered at least 3 weeks prior to receipt of 68Ga-NTA-476, and subsequent dose of chemotherapy are to resume following completion of End of Treatment Visit (EOTV), if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
o Participants on other anti-cancer therapy, such as novel anti-androgen therapy, may be allowed on a case-by-case basis at the principal investigator's discretion, with an agreement of a washout period prior to 68Ga-NTA-476 dosing, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
4. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
5. Participants must have a life expectancy of >3 months in the opinion of the Investigator.
6. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 14 days after the last injection of 68Ga-NTA-476. Participants must agree to not donate sperm during the study and for 14 days after the injection of 68Ga-NTA-476. Acceptable methods of contraception include a condom in conjunction with hormonal contraception, a vaginal ring or intrauterine device (IUD), or documented evidence of surgical sterilisation. Confirmed absence of sperm in the ejaculate is also acceptable.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
7. Have any medical condition that would, in the Investigator’s judgment, prevent the participant’s full participation in the clinical study due to safety concerns or compliance with clinical study procedures, including but not limited to participants with severe claustrophobia.
8. Residual toxicity > Grade 1 from prior/current anti-cancer therapy (except alopecia). Participants with > Grade 1 toxicity from prior anti-cancer therapy may be approved on a case-by-case basis at the principal investigator's discretion, if it is determined not to put the patient at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
9. History of uncontrolled allergic reactions and/or known or expected hypersensitivity to peptide therapeutics, including 68Ga-NTA-476 or any of its excipients.
10. Inadequate organ functions as reflected in laboratory parameters:
o Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60 mL/min or serum creatinine >1.5 x upper limit of normal (ULN)
o Platelet count of < 75 x 109/L
o Absolute neutrophil count (ANC) < 1.0 x 109/L
o Haemoglobin < 9 g/dL
o Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x ULN, or > 5 x ULN for patients with known liver metastases
o Total bilirubin > 1.5 x ULN, except for patients with documented Gilbert’s syndrome who are eligible if total bilirubin is less than or equal to 3 x ULN
11. For participants not taking warfarin or other anticoagulants: international normalised ratio (INR) less than or equal to 1.5 or prothrombin time (PT) less than or equal to 1.5 x ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) less than or equal to 1.5 x ULN. Participants taking warfarin must be on a stable dose that results in a stable INR <3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
12. Major surgery within 28 days prior to the dose of 68Ga-NTA-476. Exceptions may be approved on a case-by-case basis at the principal investigator's discretion, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
13. Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 0
Query!
Type of endpoint/s
Pharmacokinetics
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
14/08/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
14/11/2024
Query!
Actual
Query!
Date of last data collection
Anticipated
28/11/2024
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
316926
0
Commercial sector/Industry
Query!
Name [1]
316926
0
3B Pharmaceuticals
Query!
Address [1]
316926
0
Query!
Country [1]
316926
0
Germany
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Melbourne Theranostic Innovation Centre
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
319170
0
None
Query!
Name [1]
319170
0
Query!
Address [1]
319170
0
Query!
Country [1]
319170
0
Query!
Ethics approval
Ethics application status
Submitted, not yet approved
Query!
Ethics committee name [1]
315679
0
Bellberry Human Research Ethics Committee E
Query!
Ethics committee address [1]
315679
0
https://bellberry.com.au/
Query!
Ethics committee country [1]
315679
0
Australia
Query!
Date submitted for ethics approval [1]
315679
0
17/07/2024
Query!
Approval date [1]
315679
0
Query!
Ethics approval number [1]
315679
0
Query!
Summary
Brief summary
This study is investigating a new agent to be used in PET imaging for prostate cancer, called 68Ga-NTA-476. It aims to find out where 68Ga-NTA-476 goes in the body once it is injected into a person and whether there are any side effects or issues with tolerating the compound. This will be compared to an existing imaging compound which is currently used in Australia called 18F-DCFPyl. 68Ga-NTA-476 has been developed and tested in the laboratory; however, this is the first time that it will be tested in humans. It is hoped that this compound will provide more accurate PET imaging with less non-specific activity to enhance diagnostic and therapeutic outcomes. Who is it for? You may be eligible for this study if you are an adult older than 18 years of age, you have been diagnosed with prostate cancer and do not have any significant other health issues. Study details All participants who choose to participate will complete a Screening Visit to make sure that they meet the eligibility requirements for the study. Procedures completed during this visit will include demographic details, medical history, physical examination, vital signs, ECG, blood samples to check overall health status and a 18F-DCFPyl PET scan. Following confirmation of eligibility, participants will complete an Imaging Day Visit. During this visit, single dose of 68Ga-NTA-476 will be injected via a vein into the body. Following this, PET scans will be completed at about 0-30 minutes, 1 hour, and 4-6 hours. Participants will be observed in the clinical for a total of 6 hours to check vital signs and record any side effects. Between 7-9 days after this, a final study visit will be completed. Blood samples will be collected to check overall health status and the research team will check to see if any side effects were experienced. A total of 10 participants will be enrolled in this study at Melbourne Theranostic Innovation Centre in Australia
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
135482
0
Prof Rodney Hicks
Query!
Address
135482
0
Melbourne Theranostic Innovation Centre. Level 8, 14-20 Blackwood St. North Melbourne 3051
Query!
Country
135482
0
Australia
Query!
Phone
135482
0
+61 03 9454 5800
Query!
Fax
135482
0
Query!
Email
135482
0
[email protected]
Query!
Contact person for public queries
Name
135483
0
Christopher Marinakis
Query!
Address
135483
0
Melbourne Theranostic Innovation Centre. Level 8, 14-20 Blackwood St. North Melbourne 3051
Query!
Country
135483
0
Australia
Query!
Phone
135483
0
+61 03 9454 5808
Query!
Fax
135483
0
Query!
Email
135483
0
[email protected]
Query!
Contact person for scientific queries
Name
135484
0
Jason Callahan
Query!
Address
135484
0
Melbourne Theranostic Innovation Centre. Level 8, 14-20 Blackwood St. North Melbourne 3051
Query!
Country
135484
0
Australia
Query!
Phone
135484
0
+61 03 9454 5800
Query!
Fax
135484
0
Query!
Email
135484
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
PICF does not allow for sharing of IPD
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF